Efficacy of Tadalafil/Solifenacin VS Tamsulosin/Solifenacin Combination Therapy for BPH/OAB

• Status: Active, not recruiting
• Trial end date: 2022-08-01
• Target enrollment: 0
• Participant gender: Male

Summary

The investigators will compare the efficacy and safety of tadalafil/solifenacin combination therapy versus tamsulosin/solifenacin combination therapy for the treatment of BPH/OAB in a randomized controlled trial (RCT).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mansoura University
• Treatments: Solifenacin Succinate; Tadalafil; Tamsulosin

Criteria

Inclusion Criteria:

1. Ability to give informed consent and reply to questionnaires.

2. Age ≥ 45 years

3. IPSS ≥ 8

4. OABSS ≥ 5, urgency subscore ≥2

Exclusion Criteria:

1. Untreated urinary tract infection (UTI).

2. Postvoid residual (PVR) more than 150 mL

3. Neurogenic lower urinary tract dysfunction (LUTD).

4. Depression or any psychogenic disorders.

5. Diabetes mellitus, hypertension or severe cardiovascular disease.

6. Prior radiation therapy to the pelvic area.

7. Prostate cancer or bladder tumor.

8. Past history of tuberculosis

9. Allergy or contraindication to the used medications

10. Urethral stricture

11. Indwelling urethral catheter

12. Vesical stone.